Early detection slows Parkinson progression
- Trial ID
- NCT07467460
- Official Title
- NEUROTECHNO: Precision Medicine and Neurodegenerative Diseases: Advanced Systems for the Diagnosis and Treatment of Parkinson's Disease and Alzheimer's Disease.
- Goal
- Early detection slows Parkinson progression
- Status
- RECRUITING
- Sponsor
- Neuromed IRCCS
- Study Type
- OBSERVATIONAL
- Enrollment
- 500 participants
- Conditions
- PARKINSON DISEASE (Disorder), Alzheimer s Disease, Diabete Type 2
Summary For Families
Aiming to build precision medicine tools that improve diagnosis and personalize care for Parkinson's and Alzheimer's by linking clinical features with biological markers. The project is observational, collecting clinical exams, imaging and biomarkers like amyloid PET and cerebrospinal fluid measures, plus detailed medication-response data for Parkinson's, for example documented responses to L‑dopa, which is converted to dopamine to replace the brain's lost dopamine, and to dopamine agonists, so researchers can predict who will benefit from specific therapies. Recruiting about 500 adults 18 and older, it is looking for people with Parkinson's who have at least two cardinal signs including tremor or bradykinesia and no atypical features, or people with probable Alzheimer's confirmed by amyloid biomarkers; people with pre-existing psychiatric disorders, other neurodegenerative diseases, or dementia are excluded.
Locations
- IRCCS INM Neuromed, Pozzilli, Italy
Frequently Asked Questions
- What is this trial testing?
- This trial is studying an experimental treatment. Aiming to build precision medicine tools that improve diagnosis and personalize care for Parkinson's and Alzheimer's by linking clinical features with biological markers. The project is observational, collecting clinical exams, imaging and biomarkers like amyloid PET and cerebrospinal fluid measures, plus detailed medication-response data for Parkinson's, for example documented responses to L‑dopa, which is converted to dopamine to replace the brain's lost dopamine, and to dopamine agonists, so researchers can predict who will benefit from specific therapies. Recruiting about 500 adults 18 and older, it is looking for people with Parkinson's who have at least two cardinal signs including tremor or bradykinesia and no atypical features, or people with probable Alzheimer's confirmed by amyloid biomarkers; people with pre-existing psychiatric disorders, other neurodegenerative diseases, or dementia are excluded.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 years and 7 months.
- Will I get the real drug or a placebo?
- It depends on the trial design. Some Parkinson's trials are placebo controlled, meaning a portion of participants get an inactive comparison while others get the experimental treatment. Some use crossover designs so everyone eventually receives the active treatment at some point. Observational trials do not use a placebo at all because they are not testing a new treatment. The consent form for any specific trial spells out the design and your odds of being assigned to placebo before you enroll.
- How often will I need to visit the study site?
- Visit frequency varies by trial. Many Parkinson's studies require an in person visit every 4 to 12 weeks during the active treatment phase, with shorter or longer gaps depending on the design. The site coordinator can give you the full visit schedule before you sign anything, so you know what the time commitment looks like.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Will travel or parking be reimbursed?
- Many trials reimburse for parking, mileage, and sometimes lodging if the site is far from your home. Reimbursement policies vary by sponsor and site. When you contact the trial team, ask specifically what is covered and how reimbursement is processed.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.